Company: VRCA
Filing Date: 2025-12-15
Form Type: S-3
Source: 0001193125-25-319225
Chunk: 13

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-15
Form: S-3
Chunk 13
---
 S, Charlottesville, VA 22902.                              |

| (4) | “Beneficial Ownership Prior to this Offering” consists of (a) 212,201 shares of our common stock                                                                                                                                               
 issued to Mr. Goldman and related entities in the Private Placement, (b) 53,049 shares of our common stock issuable upon exercise of Common Warrants issued to Mr. Goldman and related entities in the Private Placement, (c) 58,721 shares of 
 our common stock held by Mr. Goldman and related entities prior to the Private Placement and (d) 22,471 shares of common stock issuable upon the exercise of warrants within 60 days of December 1, 2025.                                      |

| (5) | “Beneficial Ownership Prior to this Offering” consists of (a) 94,311 shares of our common stock                                                                                                                                        
 issued to Dr. Rieger in the Private Placement, (b) 23,577 shares of our common stock issuable upon exercise of Common Warrants issued to Dr. Rieger in the Private Placement, (c) 88,282 shares of our common stock held by Dr. Rieger 
 prior to the Private Placement, (d) 705 shares of our common stock held by Dr. Rieger’s immediate family members and trusts for the benefit of Dr. Rieger’s immediate family members, (e) 14,044 shares of our common stock            
 issuable upon exercise of Series B warrants held by Dr. Rieger prior to the Private Placement and (f) 77,791 shares of common stock issuable upon the exercise of options within 60 days of December 1, 2025.                          |

| (6) | “Beneficial Ownership Prior to this Offering” consists of (a) 10,000 shares of our common stock                                                                                                                                        
 issued to Mr. Zawitz in the Private Placement, (b) 2,500 shares of our common stock issuable upon exercise of Common Warrants issued to Mr. Zawitz in the Private Placement, (c) 11,000 shares of our common stock held by Mr. Zawitz  
 prior to the Private Placement (d) 25,728 shares of common stock issuable upon the exercise of options within 60 days of December 1, 2025 and (e) 2,500 shares of our common stock issuable upon exercise of Series B warrants held by 
 Mr. Zawitz prior to